Postgraduate Program in Nutrition and Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil.
PesqClin Lab, Onofre Lopes University Hospital, Brazilian Company of Hospital Services (EBSERH), Federal University of Rio Grande do Norte, Natal 59012-570, Brazil.
Nutrients. 2022 Jul 30;14(15):3154. doi: 10.3390/nu14153154.
It is already established that sarcopenia is associated with adverse outcomes; however, few studies have focused on patients who have suffered an acute cardiovascular event. The use of SARC-F, a 5-item sarcopenia screening questionnaire, in these patients remains to be investigated. We aimed to investigate whether SARC-F can predict adverse outcomes in patients admitted to a hospital with a suspected infarction. This is a 1-year prospective cohort study. During hospitalization, patients completed the SARC-F questionnaire (scores ≥ 4 considered positive for the risk of sarcopenia). Length of hospital stay (LOS), new hospital admission, myocardial infarction, and cardiovascular mortality were collected via medical records and phone interviews. In total, 180 patients were evaluated. The median age was 60.6 years; 72.3% of the participants were men, and half of the sample had comorbidities. The median SARC-F score was 1.0 (interquartile range, 0-3.0), and 21.1% of the participants screened positive. Risk of sarcopenia was independently associated with longer LOS (odds ratio, 2.34; 95% CI, 1.09-5.04; = 0.030) and hospital readmission (odds ratio, 3.73; 95% CI, 1.60-8.69; = 0.002). One-fifth of post-acute cardiovascular event patients in this cohort screened positive for sarcopenia using the SARC-F screening questionnaire. Positive scores were associated with a longer LOS and hospital readmission.
已经证实肌少症与不良结局相关；然而，很少有研究关注发生急性心血管事件的患者。SARC-F 是一种 5 项肌少症筛查问卷，尚未在这些患者中进行研究。我们旨在研究 SARC-F 是否可以预测疑似梗塞住院患者的不良结局。这是一项为期 1 年的前瞻性队列研究。住院期间，患者完成 SARC-F 问卷（评分≥4 分被认为有肌少症风险）。通过病历和电话访谈收集住院时间（LOS）、再次住院、心肌梗死和心血管死亡率。共评估了 180 名患者。中位年龄为 60.6 岁；72.3%的参与者为男性，一半的样本有合并症。中位 SARC-F 评分为 1.0（四分位距，0-3.0），21.1%的参与者筛查阳性。肌少症风险与 LOS 延长（优势比，2.34；95%置信区间，1.09-5.04；P=0.030）和再次住院（优势比，3.73；95%置信区间，1.60-8.69；P=0.002）独立相关。该队列中五分之一的急性心血管事件后患者使用 SARC-F 筛查问卷筛查为肌少症阳性。阳性评分与 LOS 延长和再次住院相关。
